Ziopharm Oncology In (ZIOP) 5.06 $ZIOP
Biotechnology Stocks Under Investors' Scanner -- Mast Therapeutics, ZIOPHARM Oncology, Amicus Therapeutics, and Repros Therapeutics
PR Newswire - Tue Jul 26, 7:30AM CDT
Biotech firms have been battling with clinical-trial costs, pricing issues, tight policies, and economic slowdowns. However, investors and analysts remain optimistic as M&A activities continue to drive industry growth, presenting buying opportunities and reasonable dividend yields. Stock-Callers.com evaluates these equities today: Mast Therapeutics Inc. (NYSE MKT: MSTX), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Repros Therapeutics Inc. (NASDAQ: RPRX). Learn more about these stocks by accessing their freenotes at:
ZIOP: 5.06 (+0.20), MSTX: 0.36 (unch), RPRX: 2.06 (-0.06), FOLD: 6.71 (-0.01)
ZIOPHARM Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Tue Jul 19, 7:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today provided an update regarding the Company's ongoing multicenter Phase I study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma.
ZIOP: 5.06 (+0.20), XON: 27.38 (+2.05)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of ZIOPHARM Oncology, Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Mon Jul 18, 11:37AM CDT
Lundin Law PC (http://lundinlawpc.com/) announces it is investigating claims against ZIOPHARM Oncology Inc. ("ZIOPHARM" or the "Company"
(Nasdaq: ZIOP) concerning possible violations of federal securities laws.
ZIOP: 5.06 (+0.20)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of ZIOPHARM Oncology, Inc.
BusinessWire - Mon Jul 18, 9:11AM CDT
Levi & Korsinsky announces it has commenced an investigation of ZIOPHARM Oncology, Inc. ("ZIOPHARM" or the "Company" (NASDAQ: ZIOP) concerning possible violations of federal securities laws.
ZIOP: 5.06 (+0.20)
ZIOPHARM (ZIOP) Stock Down on Patient Death in Phase I
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:37AM CDT
ZIOPHARM (ZIOP) announced the death of a patient in a phase I study on Ad-RTS-hIL-12 in the treatment of recurrent or progressive GBM or grade III malignant glioma.
MACK: 5.82 (+0.02), ZIOP: 5.06 (+0.20), INVA: 13.04 (+0.17), XON: 27.38 (+2.05)
Noteworthy Friday Option Activity: ZIOP, MAS, OFG
DividendChannel.com - Fri Jul 15, 2:38PM CDT
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ZIOPHARM Oncology Inc , where a total of 11,001 contracts have traded so far, representing approximately 1.1 million underlying shares. That...
ZIOP: 5.06 (+0.20)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ZIOPHARM Oncology, Inc. (ZIOP)
PR Newswire - Fri Jul 15, 12:30PM CDT
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of ZIOPHARM Oncology, Inc. ("Ziopharm" or the "Company" (NASDAQ: ZIOP). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
ZIOP: 5.06 (+0.20)
ZIOPHARM Issues Statement Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Fri Jul 15, 8:25AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today issued the following statement regarding the Company's ongoing multicenter Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma:
ZIOP: 5.06 (+0.20), XON: 27.38 (+2.05)
ZIOPHARM to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 2:00 p.m. ET. The conference is being held at the Grand Hyatt Hotel in New York City.
ZIOP: 5.06 (+0.20), XON: 27.38 (+2.05)
ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Wed May 18, 4:04PM CDT
- Data to be Presented at the 2016 ASCO Annual Meeting -
ZIOP: 5.06 (+0.20), XON: 27.38 (+2.05)
Ziopharm reports 1Q loss
Automated Insights - Tue May 10, 4:28PM CDT
BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Tuesday reported a loss of $12 million in its first quarter.
ZIOP: 5.06 (+0.20)
ZIOPHARM Reports First-Quarter 2016 Financial Results and Provides Update on Recent Activities
GlobeNewswire - Tue May 10, 4:08PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the first quarter ended March 31, 2016, and provided an update on the Company's recent activities.
ZIOP: 5.06 (+0.20), XON: 27.38 (+2.05)
Ignore MannKind Corp.: Here Are 3 Better Stocks
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 25, 9:01AM CDT
Image source: MannKind Corp. I've never seen an independent auditor report so grim as MannKind 's latest. The maker of inhalable insulin Afrezza has been in dire shape ever since marketing partner Sanofi ended their collaboration agreement,...
ZIOP: 5.06 (+0.20), CLDX: 4.67 (+0.05), XON: 27.38 (+2.05), MNKD: 1.02 (+0.03)
ZIOPHARM Announces Two Oral Presentations at ASGCT 19th Annual Meeting
GlobeNewswire - Mon Apr 18, 11:40AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced results from two programs will be presented in oral sessions at the upcoming 19 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting. The first presentation highlights preclinical data from the Company's novel viral gene therapy candidate for the controlled expression of IL-12 in combination with inhibition of programmed cell death protein 1 (PD-1) in a mouse model of glioma. The second presentation highlights preclinical data from the Company's evolution of the Sleeping Beauty (SB) non-viral transposon-transposase system in a mouse model of leukemia. The ASGCT meeting will take place May 4-7 at the Marriott Wardman Park Hotel in Washington, D.C.
ZIOP: 5.06 (+0.20), XON: 27.38 (+2.05)
ZIOPHARM to Present at the Jefferies 2nd Annual Immuno-Oncology Summit
GlobeNewswire - Thu Mar 31, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2 Annual Immuno-Oncology Summit on Thursday, April 7, 2016 at 9:35 a.m. ET. The conference is being held at the Boston Harbor Hotel in Boston, MA.
ZIOP: 5.06 (+0.20)
Of These 5 Hated Biotech Stocks, Only 1 Is a Potential Disaster in the Making
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 18, 8:03AM CDT
Image source: Flickr user Hobvias Sudoneighm. The easiest investment strategy, and the one that's proven to work best over the long run, is to pick out high-quality businesses and hold them for long periods of time. However, for some investors the...
ZIOP: 5.06 (+0.20), INSY: 15.91 (+0.26), SRPT: 25.91 (+0.63), RLYP: 31.83 (-0.11), MNKD: 1.02 (+0.03)
Could Cancer Deaths Really Be Eliminated for People Under the Age of 80 by 2050?
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 13, 8:12AM CDT
Image source: Pixabay. Cancer. It's potentially the scariest diagnosis a person can receive from their doctor, but it's something roughly 14 million people around the world will hear this year, according to the World Health Organization. In a...
ZIOP: 5.06 (+0.20), MYGN: 31.48 (+0.50), MRK: 58.66 (unch), XON: 27.38 (+2.05), EXAS: 18.11 (+0.73), BMY: 76.19 (+1.38)
Why Ziopharm Oncology Soared 49% In February
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 08, 3:02PM CST
SOURCE: MD ANDERSON CANCER CENTER W hat: After reporting that the first patient has been dosed with its second generation CAR-T cancer killing therapy on Feb. 9 and releasing its fourth quarter financials on Feb. 24, Ziopharm Oncology ...
ZIOP: 5.06 (+0.20), KITE: 57.03 (+0.40), XON: 27.38 (+2.05), JUNO: 30.86 (-0.07)
Last Week's Best Healthcare ETF
Brian Feroldi, The Motley Fool - Motley Fool - Sat Mar 05, 1:00PM CST
IMAGE BY TBIT VIA PIXABAY. It was another good week to be a healthcare-focused investor. as many of the most popular exchange-traded funds that concentrate on the sector continued to recover from their dreadful start to the year. Several of these...
MDVN: 64.08 (+0.09), ZIOP: 5.06 (+0.20), XBI: 63.57 (+1.50)
BUYINS.NET: ZIOP, CROX, CVLT, ANW, HTS, NYMT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Feb 09, 7:10AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Crocs Inc (NASDAQ:CROX), CommVault Systems Inc (NASDAQ:CVLT), Aegean Marine Petroleum Network Inc (NYSE:ANW), Hatteras Financial Corp (NYSE:HTS), New York Mortgage Trust Inc (NASDAQ:NYMT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ANW: 6.33 (-0.19), CROX: 11.44 (+0.11), ZIOP: 5.06 (+0.20), HTS: 16.29 (+0.09), CVLT: 51.68 (-0.06), NYMT: 6.55 (+0.01)
Biotechnology Stocks Under Investors' Scanner -- Mast Therapeutics, ZIOPHARM Oncology, Amicus Therapeutics, and Repros Therapeutics
PR Newswire - Tue Jul 26, 7:30AM CDT
Biotech firms have been battling with clinical-trial costs, pricing issues, tight policies, and economic slowdowns. However, investors and analysts remain optimistic as M&A activities continue to drive industry growth, presenting buying opportunities and reasonable dividend yields. Stock-Callers.com evaluates these equities today: Mast Therapeutics Inc. (NYSE MKT: MSTX), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Repros Therapeutics Inc. (NASDAQ: RPRX). Learn more about these stocks by accessing their freenotes at:
ZIOP: 5.06 (+0.20), MSTX: 0.36 (unch), RPRX: 2.06 (-0.06), FOLD: 6.71 (-0.01)
ZIOPHARM Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Tue Jul 19, 7:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today provided an update regarding the Company's ongoing multicenter Phase I study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma.
ZIOP: 5.06 (+0.20), XON: 27.38 (+2.05)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of ZIOPHARM Oncology, Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Mon Jul 18, 11:37AM CDT
Lundin Law PC (http://lundinlawpc.com/) announces it is investigating claims against ZIOPHARM Oncology Inc. ("ZIOPHARM" or the "Company"
(Nasdaq: ZIOP) concerning possible violations of federal securities laws. ZIOP: 5.06 (+0.20)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of ZIOPHARM Oncology, Inc.
BusinessWire - Mon Jul 18, 9:11AM CDT
Levi & Korsinsky announces it has commenced an investigation of ZIOPHARM Oncology, Inc. ("ZIOPHARM" or the "Company"
(NASDAQ: ZIOP) concerning possible violations of federal securities laws. ZIOP: 5.06 (+0.20)
ZIOPHARM (ZIOP) Stock Down on Patient Death in Phase I
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:37AM CDT
ZIOPHARM (ZIOP) announced the death of a patient in a phase I study on Ad-RTS-hIL-12 in the treatment of recurrent or progressive GBM or grade III malignant glioma.
MACK: 5.82 (+0.02), ZIOP: 5.06 (+0.20), INVA: 13.04 (+0.17), XON: 27.38 (+2.05)
Noteworthy Friday Option Activity: ZIOP, MAS, OFG
DividendChannel.com - Fri Jul 15, 2:38PM CDT
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ZIOPHARM Oncology Inc , where a total of 11,001 contracts have traded so far, representing approximately 1.1 million underlying shares. That...
ZIOP: 5.06 (+0.20)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ZIOPHARM Oncology, Inc. (ZIOP)
PR Newswire - Fri Jul 15, 12:30PM CDT
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of ZIOPHARM Oncology, Inc. ("Ziopharm" or the "Company"
(NASDAQ: ZIOP). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484. ZIOP: 5.06 (+0.20)
ZIOPHARM Issues Statement Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Fri Jul 15, 8:25AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today issued the following statement regarding the Company's ongoing multicenter Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma:
ZIOP: 5.06 (+0.20), XON: 27.38 (+2.05)
ZIOPHARM to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 2:00 p.m. ET. The conference is being held at the Grand Hyatt Hotel in New York City.
ZIOP: 5.06 (+0.20), XON: 27.38 (+2.05)
ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Wed May 18, 4:04PM CDT
- Data to be Presented at the 2016 ASCO Annual Meeting -
ZIOP: 5.06 (+0.20), XON: 27.38 (+2.05)
Ziopharm reports 1Q loss
Automated Insights - Tue May 10, 4:28PM CDT
BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Tuesday reported a loss of $12 million in its first quarter.
ZIOP: 5.06 (+0.20)
ZIOPHARM Reports First-Quarter 2016 Financial Results and Provides Update on Recent Activities
GlobeNewswire - Tue May 10, 4:08PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the first quarter ended March 31, 2016, and provided an update on the Company's recent activities.
ZIOP: 5.06 (+0.20), XON: 27.38 (+2.05)
Ignore MannKind Corp.: Here Are 3 Better Stocks
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 25, 9:01AM CDT
Image source: MannKind Corp. I've never seen an independent auditor report so grim as MannKind 's latest. The maker of inhalable insulin Afrezza has been in dire shape ever since marketing partner Sanofi ended their collaboration agreement,...
ZIOP: 5.06 (+0.20), CLDX: 4.67 (+0.05), XON: 27.38 (+2.05), MNKD: 1.02 (+0.03)
ZIOPHARM Announces Two Oral Presentations at ASGCT 19th Annual Meeting
GlobeNewswire - Mon Apr 18, 11:40AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced results from two programs will be presented in oral sessions at the upcoming 19 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting. The first presentation highlights preclinical data from the Company's novel viral gene therapy candidate for the controlled expression of IL-12 in combination with inhibition of programmed cell death protein 1 (PD-1) in a mouse model of glioma. The second presentation highlights preclinical data from the Company's evolution of the Sleeping Beauty (SB) non-viral transposon-transposase system in a mouse model of leukemia. The ASGCT meeting will take place May 4-7 at the Marriott Wardman Park Hotel in Washington, D.C.
ZIOP: 5.06 (+0.20), XON: 27.38 (+2.05)
ZIOPHARM to Present at the Jefferies 2nd Annual Immuno-Oncology Summit
GlobeNewswire - Thu Mar 31, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2 Annual Immuno-Oncology Summit on Thursday, April 7, 2016 at 9:35 a.m. ET. The conference is being held at the Boston Harbor Hotel in Boston, MA.
ZIOP: 5.06 (+0.20)
Of These 5 Hated Biotech Stocks, Only 1 Is a Potential Disaster in the Making
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 18, 8:03AM CDT
Image source: Flickr user Hobvias Sudoneighm. The easiest investment strategy, and the one that's proven to work best over the long run, is to pick out high-quality businesses and hold them for long periods of time. However, for some investors the...
ZIOP: 5.06 (+0.20), INSY: 15.91 (+0.26), SRPT: 25.91 (+0.63), RLYP: 31.83 (-0.11), MNKD: 1.02 (+0.03)
Could Cancer Deaths Really Be Eliminated for People Under the Age of 80 by 2050?
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 13, 8:12AM CDT
Image source: Pixabay. Cancer. It's potentially the scariest diagnosis a person can receive from their doctor, but it's something roughly 14 million people around the world will hear this year, according to the World Health Organization. In a...
ZIOP: 5.06 (+0.20), MYGN: 31.48 (+0.50), MRK: 58.66 (unch), XON: 27.38 (+2.05), EXAS: 18.11 (+0.73), BMY: 76.19 (+1.38)
Why Ziopharm Oncology Soared 49% In February
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 08, 3:02PM CST
SOURCE: MD ANDERSON CANCER CENTER W hat: After reporting that the first patient has been dosed with its second generation CAR-T cancer killing therapy on Feb. 9 and releasing its fourth quarter financials on Feb. 24, Ziopharm Oncology ...
ZIOP: 5.06 (+0.20), KITE: 57.03 (+0.40), XON: 27.38 (+2.05), JUNO: 30.86 (-0.07)
Last Week's Best Healthcare ETF
Brian Feroldi, The Motley Fool - Motley Fool - Sat Mar 05, 1:00PM CST
IMAGE BY TBIT VIA PIXABAY. It was another good week to be a healthcare-focused investor. as many of the most popular exchange-traded funds that concentrate on the sector continued to recover from their dreadful start to the year. Several of these...
MDVN: 64.08 (+0.09), ZIOP: 5.06 (+0.20), XBI: 63.57 (+1.50)
BUYINS.NET: ZIOP, CROX, CVLT, ANW, HTS, NYMT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Feb 09, 7:10AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Crocs Inc (NASDAQ:CROX), CommVault Systems Inc (NASDAQ:CVLT), Aegean Marine Petroleum Network Inc (NYSE:ANW), Hatteras Financial Corp (NYSE:HTS), New York Mortgage Trust Inc (NASDAQ:NYMT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ANW: 6.33 (-0.19), CROX: 11.44 (+0.11), ZIOP: 5.06 (+0.20), HTS: 16.29 (+0.09), CVLT: 51.68 (-0.06), NYMT: 6.55 (+0.01)
